BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

3637

530019

JUBLPHARMA

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

JUBILANT PHARMOVA LTD performance

Today’s low

Today’s high

₹ 866.30 ₹ 905.10
₹ 897.95

52 week low

52 week high

₹ 617.05 ₹ 1309.90
₹ 897.95

Open Price

₹ 887.50

Prev. Close

₹ 894.70

Volume (Shares)

278779.00

Total traded value

₹ 2503.29

Upper Circuit

₹ 1073.60

Lower Circuit

₹ 715.80

info

JUBILANT PHARMOVA LTD Share Price Update

As of the latest trading session, JUBILANT PHARMOVA LTD share price is currently at ₹ 885.1, which is down by ₹ -9.60 from its previous closing. Today, the stock has fluctuated between ₹ 866.30 and ₹ 905.10. Over the past year, JUBILANT PHARMOVA LTD has achieved a return of 33.18 %. In the last month alone, the return has been -2.07 %. Read More...

JUBILANT PHARMOVA LTD fundamentals


  • Market cap (Cr)

    14,015.62

  • P/E Ratio (TTM)

    375.44

  • Beta

    0.94

  • Book Value / share

    144.29

  • Return on equity

    1.32%

  • EPS (TTM)

    3.09

  • Dividend yield

    0.56%

  • Net profit/quarter (Cr)

    5.30

info icon alternate text
  • Market cap (Cr)

    14,208.81

  • P/E Ratio (TTM)

    375.44

  • Beta

    0.88

  • Book Value / share

    144.29

  • Return on equity

    1.32%

  • EPS (TTM)

    3.09

  • Dividend yield

    0.56%

  • Net profit/quarter (Cr)

    5.30

info icon alternate text

JUBILANT PHARMOVA LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 193.40
Operating Expense 205.70
Net Profit 5.30
Net Profit Margin (%) 2.74
Earnings Per Share (EPS) 0.33
EBITDA 29.40
Effective Tax Rate (%) 39.08
Particulars SEP 2024 (Values in Cr)
Revenue 162.60
Operating Expense 192.90
Net Profit 10.50
Net Profit Margin (%) 6.45
Earnings Per Share (EPS) 0.66
EBITDA 37.70
Effective Tax Rate (%) 36.74
Particulars JUN 2024 (Values in Cr)
Revenue 162.70
Operating Expense 186.20
Net Profit -10.20
Net Profit Margin (%) -6.26
Earnings Per Share (EPS) -0.64
EBITDA 9.50
Effective Tax Rate (%) 8.92
Particulars MAR 2024 (Values in Cr)
Revenue 201.70
Operating Expense 214.40
Net Profit 32.50
Net Profit Margin (%) 16.11
Earnings Per Share (EPS) 2.05
EBITDA 62.30
Effective Tax Rate (%) 21.68
Particulars DEC 2023 (Values in Cr)
Revenue 170.20
Operating Expense 196.50
Net Profit -2.40
Net Profit Margin (%) -1.41
Earnings Per Share (EPS) -0.15
EBITDA 18.30
Effective Tax Rate (%) -4.34
Particulars MAR 2024 (Values in Cr)
Revenue 755.20
Operating Expense 846.40
Net Profit 31.60
Net Profit Margin (%) 4.18
Earnings Per Share (EPS) 1.99
EBITDA 119.89
Effective Tax Rate (%) 24.22
Particulars MAR 2023 (Values in Cr)
Revenue 774.40
Operating Expense 868.70
Net Profit 49.90
Net Profit Margin (%) 6.44
Earnings Per Share (EPS) 3.13
EBITDA 141.00
Effective Tax Rate (%) 37.07
Particulars MAR 2022 (Values in Cr)
Revenue 701.14
Operating Expense 767.17
Net Profit 80.49
Net Profit Margin (%) 11.47
Earnings Per Share (EPS) 5.05
EBITDA 132.62
Effective Tax Rate (%) 4.99
Particulars MAR 2021 (Values in Cr)
Revenue 2688.07
Operating Expense 2484.21
Net Profit 214.48
Net Profit Margin (%) 7.97
Earnings Per Share (EPS) 13.47
EBITDA 474.94
Effective Tax Rate (%) 21.48
Particulars MAR 2020 (Values in Cr)
Revenue 3095.02
Operating Expense 3012.58
Net Profit 321.14
Net Profit Margin (%) 10.37
Earnings Per Share (EPS) 20.16
EBITDA 542.43
Effective Tax Rate (%) -7.46
Particulars MAR 2024 (Values in Cr)
Book Value / Share 343.92
ROE % 0.76
ROCE % 6.37
Total Debt to Total Equity 0.68
EBITDA Margin 14.82
Particulars MAR 2023 (Values in Cr)
Book Value / Share 339.58
ROE % -7.33
ROCE % 3.05
Total Debt to Total Equity 0.64
EBITDA Margin 13.21
Particulars MAR 2022 (Values in Cr)
Book Value / Share 334.10
ROE % 8.21
ROCE % 9.52
Total Debt to Total Equity 0.60
EBITDA Margin 18.88
Particulars MAR 2021 (Values in Cr)
Book Value / Share 297.85
ROE % 16.55
ROCE % 11.86
Total Debt to Total Equity 0.74
EBITDA Margin 23.48
Particulars MAR 2020 (Values in Cr)
Book Value / Share 351.78
ROE % 17.25
ROCE % 14.09
Total Debt to Total Equity 0.93
EBITDA Margin 29.67
Particulars MAR 2024 (Values in Cr)
Book Value / Share 149.34
ROE % 1.32
ROCE % 2.57
Total Debt to Total Equity 0.15
EBITDA Margin 15.28
Particulars MAR 2023 (Values in Cr)
Book Value / Share 151.86
ROE % 2.70
ROCE % 4.27
Total Debt to Total Equity 0.23
EBITDA Margin 17.41
Particulars MAR 2022 (Values in Cr)
Book Value / Share 80.47
ROE % 6.12
ROCE % 6.29
Total Debt to Total Equity 0.39
EBITDA Margin 135.72
Particulars MAR 2021 (Values in Cr)
Book Value / Share 80.51
ROE % 11.03
ROCE % 11.58
Total Debt to Total Equity 0.65
EBITDA Margin 17.53
Particulars MAR 2020 (Values in Cr)
Book Value / Share 163.67
ROE % 12.98
ROCE % 9.90
Total Debt to Total Equity 0.75
EBITDA Margin 17.28
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 956.80
Total Assets 11548.50
Total Liabilities 11548.50
Total Equity 5421.10
Share Outstanding 158350737
Price to Book Ratio 3.81
Return on Assets (%) 0.66
Return on Capital (%) 0.87
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1014.30
Total Assets 11156.70
Total Liabilities 11156.70
Total Equity 5391.80
Share Outstanding 159281139
Price to Book Ratio 1.84
Return on Assets (%) -0.54
Return on Capital (%) -0.69
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 984.23
Total Assets 9990.86
Total Liabilities 9990.86
Total Equity 5316.40
Share Outstanding 159281139
Price to Book Ratio 4.82
Return on Assets (%) 4.14
Return on Capital (%) 5.02
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 671.31
Total Assets 8918.11
Total Liabilities 8918.11
Total Equity 4741.51
Share Outstanding 159281139
Price to Book Ratio 8.45
Return on Assets (%) 9.37
Return on Capital (%) 11.41
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1399.87
Total Assets 12521.65
Total Liabilities 12521.65
Total Equity 5603.88
Share Outstanding 159281139
Price to Book Ratio 1.52
Return on Assets (%) 7.17
Return on Capital (%) 8.99
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 36.10
Total Assets 2991.90
Total Liabilities 2991.90
Total Equity 2374.50
Share Outstanding 159281139
Price to Book Ratio 3.81
Return on Assets (%) 1.05
Return on Capital (%) 1.16
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 11.00
Total Assets 3008.40
Total Liabilities 3008.40
Total Equity 2414.50
Share Outstanding 159281139
Price to Book Ratio 1.84
Return on Assets (%) 1.65
Return on Capital (%) 1.84
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 22.50
Total Assets 1829.47
Total Liabilities 1829.47
Total Equity 1281.81
Share Outstanding 159281139
Price to Book Ratio 4.82
Return on Assets (%) 4.29
Return on Capital (%) 4.41
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 40.32
Total Assets 1844.59
Total Liabilities 1844.59
Total Equity 1282.44
Share Outstanding 159281139
Price to Book Ratio 8.45
Return on Assets (%) 11.62
Return on Capital (%) 12.08
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 257.73
Total Assets 5433.38
Total Liabilities 5433.38
Total Equity 2607.29
Share Outstanding 159281139
Price to Book Ratio 1.52
Return on Assets (%) 5.91
Return on Capital (%) 7.05
Particulars MAR 2024 (Values in Cr)
Net Income 170.50
Cash from Operations 1179.00
Cash from Investing -607.90
Cash from Financing -432.50
Net change in Cash -57.50
Free Cash Flow 2076.70
Particulars MAR 2023 (Values in Cr)
Net Income 27.80
Cash from Operations 865.00
Cash from Investing -544.40
Cash from Financing -156.70
Net change in Cash 30.10
Free Cash Flow 1679.50
Particulars MAR 2022 (Values in Cr)
Net Income 630.44
Cash from Operations 1031.63
Cash from Investing -380.37
Cash from Financing -32.59
Net change in Cash 481.86
Free Cash Flow 1631.62
Particulars MAR 2021 (Values in Cr)
Net Income 1212.01
Cash from Operations 2178.38
Cash from Investing -739.01
Cash from Financing -1709.38
Net change in Cash -651.87
Free Cash Flow 2705.87
Particulars MAR 2020 (Values in Cr)
Net Income 1210.53
Cash from Operations 1791.59
Cash from Investing -327.00
Cash from Financing -1050.37
Net change in Cash 225.41
Free Cash Flow 2365.75
Particulars MAR 2024 (Values in Cr)
Net Income 41.70
Cash from Operations 155.40
Cash from Investing -40.30
Cash from Financing -77.80
Net change in Cash 25.10
Free Cash Flow 223.00
Particulars MAR 2023 (Values in Cr)
Net Income 79.30
Cash from Operations -47.70
Cash from Investing 31.10
Cash from Financing 22.50
Net change in Cash -11.50
Free Cash Flow 11.89
Particulars MAR 2022 (Values in Cr)
Net Income 82.24
Cash from Operations 15.82
Cash from Investing 93.10
Cash from Financing -107.37
Net change in Cash -17.82
Free Cash Flow 17.77
Particulars MAR 2021 (Values in Cr)
Net Income 273.16
Cash from Operations 650.97
Cash from Investing 177.95
Cash from Financing -781.64
Net change in Cash 4.68
Free Cash Flow 743.77
Particulars MAR 2020 (Values in Cr)
Net Income 298.83
Cash from Operations 336.78
Cash from Investing -197.71
Cash from Financing -41.04
Net change in Cash 78.00
Free Cash Flow 534.34
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

JUBILANT PHARMOVA LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
897.95 0.36 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 906.00
  • 26 Days 909.90
  • 10 Days 909.30
  • 50 Days 923.90
  • 12 Days 909.40
  • 100 Days 953.50
  • 20 Days 909.00
  • 200 Days 931.90
897.85 PIVOT

First Support

876.85

First Resistance

915.70

Second Support

859.00

Second Resistance

936.70

Third Support

838.00

Third Resistance

954.55

RSI

47.46

ADX

4.88

MACD

-0.56

Williams % R

-48.58

Commodity Channel Index (CCI)

-66.25

Date

2025-04-30

Week

109406.00

Same Day

99075.00

Month

101732.00

1 Year

0.95

3 Year

1.02

Over 1 Month

-2.07%

down

Over 1 Year

33.18%

down

Over 3 Months

-6.18%

down

Over 3 Years

24.99%

down

Over 6 Months

-20.67%

down

Over 5 Years

20.92%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

JUBILANT PHARMOVA LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
25.05%
Promoter Holdings
50.67%
FII
17.22%
DII
7.04%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Spb Trustee Company Pvt Ltd 3.2686161E7 (20.52%) Shareholding of Promoter and Promoter Group
Hsb Trustee Company Pvt Ltd 3.0257475E7 (19.0%) Shareholding of Promoter and Promoter Group
East Bridge Capital Master Fund I Ltd 6842321.0 (4.3%) Public Shareholding
Government Pension Fund Global 5519609.0 (3.47%) Public Shareholding
Miller Holdings Pte Ltd 5230455.0 (3.28%) Shareholding of Promoter and Promoter Group
Rekha Jhunjhunwala 5224000.0 (3.28%) Public Shareholding
Rekha Jhunjhunwala 5020000.0 (3.15%) Public Shareholding
Mav Management Advisors Llp 5011400.0 (3.15%) Shareholding of Promoter and Promoter Group
Nikita Resources Private Limited 3504540.0 (2.2%) Shareholding of Promoter and Promoter Group
Quant Mutual Fund - Quant Small Cap Fund 2947185.0 (1.85%) Public Shareholding
Theleme India Master Fund Limited 2324887.0 (1.46%) Public Shareholding
Jubilant Enpro Private Limited 2116000.0 (1.33%) Shareholding of Promoter and Promoter Group
Sbi Life Insurance Co. Ltd 2098797.0 (1.32%) Public Shareholding
Abakkus Emerging Opportunities Fund-1 1877576.0 (1.18%) Public Shareholding
Priyavrat Bhartia 1398010.0 (0.88%) Shareholding of Promoter and Promoter Group
Hari Shanker Bhartia 360885.0 (0.23%) Shareholding of Promoter and Promoter Group
Shamit Bhartia 129245.0 (0.08%) Shareholding of Promoter and Promoter Group
Kavita Bhartia 10285.0 (0.01%) Shareholding of Promoter and Promoter Group
Rance Investment Holdings Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Cumin Investments Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Torino Overseas Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Shyam Sunder Bhartia 5000.0 (0.0%) Shareholding of Promoter and Promoter Group
Jubilant Advisors Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Jubilant Consumer Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Vam Holdings Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Jaytee Private Limited 7600.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

JUBILANT PHARMOVA LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
10 Aug 2023 5.0 Final 10 Aug 2023 Equity shares
11 Aug 2022 5.0 Final 12 Aug 2022 Equity shares
05 Aug 2021 5.0 Final 06 Aug 2021 Equity shares
09 Mar 2020 5.0 Interim 11 Mar 2020 Equity shares
12 Sep 2019 4.5 Final 14 Sep 2019 Equity shares
12 Sep 2018 3.0 Final 15 Sep 2018 Equity shares
16 Aug 2017 3.0 Final 19 Aug 2017 Equity shares
18 Aug 2016 3.0 Final 20 Aug 2016 Equity shares
20 Aug 2015 3.0 Final 22 Aug 2015 Equity shares
21 Aug 2014 3.0 Final 23 Aug 2014 Equity shares
14 Aug 2013 3.0 Final 17 Aug 2013 Equity shares
14 Aug 2012 3.0 Final 17 Aug 2012 Equity shares
10 Aug 2011 2.0 Final 12 Aug 2011 Equity shares
17 Sep 2010 2.0 Final 21 Sep 2010 Equity shares
29 Jun 2009 1.5 Final 01 Jul 2009 Equity shares
17 Sep 2008 1.5 Final 19 Sep 2008 Equity shares
17 Sep 2007 1.25 Final 19 Sep 2007 Equity shares
08 Sep 2006 0.0 Final 12 Sep 2006 Equity shares
Ex-Date Ex-Bonus Ratio
15 Mar 2004 12 Mar 2004 3:5
Ex-Date Old FV NEW FV Record Date
17 Mar 2006 5.0 1.0 24 Mar 2006
12 Nov 2002 10.0 5.0 21 Nov 2002
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
10 Aug 2023 5.0 Final 10 Aug 2023 Equity shares
11 Aug 2022 5.0 Final 12 Aug 2022 Equity shares
05 Aug 2021 5.0 Final 06 Aug 2021 Equity shares
09 Mar 2020 5.0 Interim 11 Mar 2020 Equity shares
12 Sep 2019 4.5 Final 14 Sep 2019 Equity shares
12 Sep 2018 3.0 Final 15 Sep 2018 Equity shares
16 Aug 2017 3.0 Final 19 Aug 2017 Equity shares
18 Aug 2016 3.0 Final 20 Aug 2016 Equity shares
20 Aug 2015 3.0 Final 22 Aug 2015 Equity shares
21 Aug 2014 3.0 Final 23 Aug 2014 Equity shares
14 Aug 2013 3.0 Final 17 Aug 2013 Equity shares
14 Aug 2012 3.0 Final 17 Aug 2012 Equity shares
10 Aug 2011 2.0 Final 12 Aug 2011 Equity shares
17 Sep 2010 2.0 Final 21 Sep 2010 Equity shares
29 Jun 2009 1.5 Final 01 Jul 2009 Equity shares
17 Sep 2008 1.5 Final 19 Sep 2008 Equity shares
17 Sep 2007 1.25 Final 19 Sep 2007 Equity shares
08 Sep 2006 0.0 Final 12 Sep 2006 Equity shares
Ex-Date Ex-Bonus Ratio
15 Mar 2004 12 Mar 2004 3:5
Ex-Date Old FV NEW FV Record Date
17 Mar 2006 5.0 1.0 24 Mar 2006
12 Nov 2002 10.0 5.0 21 Nov 2002

JUBILANT PHARMOVA LTD Share Price

Jubilant Pharmova Limited, (Formerly known as Jubilant Life Sciences Limited), is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions. The Company is engaged in pharmaceuticals, contract research and development services and proprietary novel drugs. The pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of Active Pharmaceutical Ingredients (APIs), Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non-Sterile Products through 6 US FDA approved manufacturing facilities in India, USA and Canada with a network of over 48 radiopharmacies in the USA. The contract research and development segment provides drug discovery and development services as well as clinical data software and service solutions. . Proprietary novel drugs segment is a patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.

The Company was incorporated in 21st June, 1978. The Company tapped capital market in the year 1981 by the way of its Initial Public Offering (IPO). During the year 1983, the company's commercial production of Vinyl Acetate Monomer (VAM was started to enhance the value of the company. Research & Development center of the company got recognition from Government of India in the year 1985. JLSL had introduced new products in Performance Chemicals segments during the period of 1987, Poly vinyl acetate emulsion for paint, textile, paper & packaging and woodworking industry. In 1988, the company had launched its first branded product under the name of Vamicol, an adhesive product. The plant for Pyridine & Picoline was started in the year 1990 and also the company received an ISO 9001 certification for its well known quality systems in the year 1995. During the year 1997, the first Multi-purpose fine chemicals plant was gone to stream and also the plant for food polymer was commissioned. After a year, in 1998, JLSL had entered into high value-added Pyridine derivates, commissioned Pyridine HBR and Cyano Pyridine plants. also in the same year, the company had formed marketing subsidiary in the USA and acquired acetyl plant in western India. The Company had penetrated the Bio / chemo informatics arena by setting up Jubilant Biosys Ltd in the year 2000.

During the year 2001, the company had changed its corporate and business profile, due to this; the new corporate identity was born as Jubilant Life Sciences Ltd. JLSL had acquired the Active Pharmaceutical Ingredients (API) business in the period of 2002. The new state-of-the-art Research & Development Centre of the company in Noida, near New Delhi was established in the year 2003 with all latest scientific instruments. The Company bagged Golden Peacock award for Innovation Management for the year 2003. During the year 2004, JLSL had set up medicinal chemistry services business through wholly owned subsidiary Jubilant Chemsys Ltd and also entered into formulations & regulatory affairs businesses by acquiring Pharmaceuticals Services. In the same year the company had incorporated, N.V. and PSI Supply N.V., the pharmaceutical companies in Europe. JLSL had received C Acharya Award for Development of Indigenous Technology from ICMA for the year 2004.

JLSL had acquired the Target Research Associates, Inc in the year of 2005 and renamed Clinsys Inc.; a US based Clinical Research Organisation (CRO). Also in the same year, the company had acquired Trinity Laboratories, Inc. and its wholly owned subsidiary, Trigen Laboratories, Inc., renamed Jubilant Pharmaceuticals, Inc., a generic pharmaceutical company in USA having a US FDA approved formulations manufacturing facility. JLSL had embarked into Clinsys business by setting up wholly owned subsidiary under the name and style of Jubilant Clinsys Ltd. Jubilant's state-of-the-art Drug Discovery facility was inaugurated in Bangalore during November of the year 2006, the largest of its kind in India for providing integrated Drug Discovery solutions.

As of June 2007, JLSL had completed the largest overseas acquisition in Contract Manufacturing by an Indian company, through its purchase of Hollister-Stier Laboratories (Hollister). A multi-million dollar long term agreement was signed with Syngenta in September of the year 2007 for the supply of Pyridines. In December of the year 2007, the company and Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc had entered into a collaboration agreement through Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd to discover small molecule drug candidates for a novel metabolic disorders target.

JLSL had completed the transaction effective May of the year 2008, to acquire Canada based Draxis Speciality Pharmaceuticals Inc. (Draxis) for US$ 253 million and also in the same month of the same year, the company had acquired Speciality Molecules Pvt. Ltd., a niche manufacturer of Speciality Intermediates with manufacturing facilities located in Ambarnath (near Mumbai) in India for Rs. 199.5 million. The Company and Amgen Inc, Thousand Oaks, California, the largest US based Biotech Company, made a drug discovery partnership in July of the year 2008 through Jubilant Biosys Ltd subsidiary of Jubilant Organosys, under which Amgen and Jubilant collaborate to develop a portfolio of novel drugs in new target areas of interest across multiple therapeutic areas.

During the year 2009-10, in line with continued strategy of enhancing its focus as a Pharmaceuticals and Life sciences company, the demerger of the Agri and Performance Polymer division into a separate company was approved in principle by the management on January 21, 2010. The demerged entity is Jubilant Industries Ltd where as the name of Jubilant Organosys is changed to Jubilant Life Sciences Ltd.

During the year 2011-12, the company set up global plants of Vitamin B3 and 3-Cyanopyridine, at Special Economic Zone making it the largest producer of Vitamin B3 in India and scond largest globally. It is also setting up a manufacturing plant at SEZ for Symtet, a crop science ingredient for one of the world's largest and safest low cost insecticide through an environment friently process.

During the year 2013-14, the company sold its Hospital business to Narayana Health. The business has been transferred on a going concern basis as a slump sale, which will enable it to focus on its core businesses in Pharmaceuticals and Life Sciences.

In 2014-15, the company completed the consolidation of all its Pharmaceutical business under Jubilant Pharma, Singapore with effect from July 1, 2014.

On 24 March 2014, Jubilant Chemsys, a wholly-owned subsidiary of Jubilant Life Sciences, announced an extension of collaborative partnership with Infectious Disease Research Institute (IDRI) for TB drug discovery. The collaboration in chemistry support has been in existence since 2009 as part of a joint effort with the Lilly TB Drug Discovery Initiative (LTI) and so far has generated hundreds of Novel Chemical Entities (NCEs) - some of which have now been identified for further exploration. Jubilant Chemsys, under the terms of agreement, so far had been offering philanthropic support and expertise in synthesis of NCEs to support the early research in TB. Jubilant Chemsys offers drug discovery research services on Full Time Equivalent and Fees- for-services basis.

On 13 May 2014, Jubilant Biosys, a Bengaluru-based subsidiary of Jubilant Life Sciences, and Orion Corporation (Orion), the largest pharmaceutical company in Finland, announced a path breaking drug discovery collaboration to discover small molecule inhibitors in neuroscience therapeutic area. The research deal is aimed at developing drug that can benefit large population of people with unmet needs in the pain management area. As per the terms of agreement, Jubilant's extensive experience in drug discovery and pre-clinical development will be utilised by Orion to address pain management needs of Central Nervous System (CNS). Jubilant will offer integrated drug discovery services across early discovery, synthetic and medicinal chemistry including scale up and pre-clinical services. The research for the project, which has been initiated, will be undertaken primarily at state-of-the-art R&D labs of Jubilant Biosys (India) and some parts at Jubilant Discovery Center, USA.

On 26 May 2014, Jubilant Life Sciences announced that IFC, a member of the World Bank Group, is lending $147.5 million to Jubilant Pharma Limited, a wholly owned subsidiary of Jubilant Life Sciences Limited, to enable better access to quality and affordable pharmaceuticals in underserved markets in India and across the world. Of the total financing package, $110 million is from IFC's own account. The remaining $37.5 million is from IFC's Managed Co-Lending Portfolio Program, which provides additional long-term financing through co-financing partners. The loan will help Jubilant Life Sciences increase focus on the pharmaceutical sector and strengthen its generic drug manufacturing facilities in India.

On 30 September 2014, BioResource International, Inc. (BRI), a global biotechnology company specializing in the research, development and manufacture of high-performance, cost effective enzyme solutions for animal nutrition, signed a marketing agreement with Jubilant Life Sciences for marketing and distribution of selected feed enzyme products in South Asia. Jubilant will be the exclusive marketing partner of BRI's Xylamax and XylaQuick products in South Asia. Jubilant will market and distribute Xylamax and XylaQuick to large volume poultry producers, feed integrators, and animal health and nutrition consultants throughout India, Pakistan, Sri Lanka, Nepal, Bangladesh and Bhutan.

On 23 December 2014, Jubilant Life Sciences Limited announced that its indirect wholly-owned subsidiary, Jubilant Generics Inc. (Jubilant Generics), has successfully completed its previously announced Tender Offer for all of the outstanding shares of Cadista Holdings Inc. (Cadista Holdings) common stock not owned by Jubilant Generics or its affiliates. Jubilant Life Sciences has caused Jubilant Generics to complete a short-form merger with and into Cadista Holdings. No vote of Cadista Holdings' stockholders was required in connection with the merger. As a result of the merger, all shares of Cadista Holdings held by the remaining minority stockholders of Cadista Holdings have been cancelled and, subject to appraisal rights under Delaware Law, converted into the right to receive a $1.60 per share in cash, without interest and less any required withholding taxes, the same consideration paid in the Tender Offer. Accordingly, Cadista Holdings has now become a wholly-owned subsidiary of Jubilant Life Sciences Limited.

On 12 June 2015, Jubilant Life Sciences announced that its subsidiary, Jubilant HollisterStier has been informed by the US Food and Drug Administration (USFDA) that its pharmaceutical sterile manufacturing facility in Spokane, Washington (USA) has been upgraded to the status of Voluntary Action Indicated (VAI). The Spokane site's latest Establishment Inspection Report (EIR) indicates the inspections in April 2014 and December 2014 have been successfully concluded. This upgradation by the USFDA from Official Action Indicated (OAI) to VAI is indicative of the cGMP status at the facility since receiving the warning letter in 2013.

On 7 January 2016, Jubilant Biosys Ltd, a Bengaluru based subsidiary of Jubilant Life Sciences Ltd, and Sanofi Deutschland GmbH, Frankfurt, Germany, announced a strategic alliance to discover and develop small molecule inhibitors for multiple targets in the metabolic disorders therapeutic area. The research alliance is aimed at developing therapeutic small molecules that will address the unmet needs in diabetes and obesity. As per the terms of the agreement, Jubilant shall provide Sanofi integrated drug discovery and early development services across computational, synthetic chemistry, biology, GLP/ GMP services, to identify lead candidates and demonstrate clinical proof of mechanism in the metabolic disorders therapeutic areas. The research for the projects, which has been initiated, will be undertaken primarily at state-of-the-art R&D labs of Jubilant Biosys (Bengaluru, India) and Jubilant Chemsys (Noida, India).

On 6 February 2016, Jubilant Life Sciences announced that China's Ministry of Commerce reduced Anti-Dumping Duty on its Pyridine to 17.6% from existing 24.6% based on the review petition filed by the company. The company will continue to evaluate the market conditions and get the benefit of reduced duty going forward.

On 4 January 2017, Jubilant Life Sciences announced that its wholly own subsidiary Jubilant Pharma Limited, through one of its units Jubilant DraxImage Inc. Montreal Canada (JDI), has signed long term contracts with distribution networks in the US for supply of products used for diagnostic and therapeutic procedures for thyroid, myocardial perfusion, lung, kidney and bone scans to be supplied by JDI over a period of 39 months effective from January 2017.

On 25 May 2017, Jubilant Life Sciences announced a price increase of up to 15% for its Vitamin B3 (Niacin & Niacinamide) with immediate effect, for non-contract customers and wherever existing contracts permit. This is further to the price increase of up to 15% announced in December 2016

On 21 June 2017, Jubilant Life Sciences announced a strategic partnership with Barentz International, an international leader in the distribution of high-quality ingredients. The two companies have signed a commercial agreement to work together within the food & nutrition market in India and its neighbouring countries. The collaboration aims at delivering solutions in food nutrition and fortification. Working with world class suppliers, Barentz offers a full portfolio of single specialty ingredients for food & beverages, as well as custom nutritional and functional blends, produced at Barentz state-of-the-art production facilities Vitablend in Singapore. Jubilant is the world's second largest producer of Vitamin B3 (Niacinamide and Niacin), a vitamin that is extensively used in dietary food supplements, enrichment of breakfast cereals and flour, beverages and energy drinks, infant formulas, baking and confectionary. Together the two companies hope to make a significant impact in the area of micronutrient deficiency through solutions in food nutrition and fortification.

On 1 September 2017, Jubilant Life Sciences Ltd announced that Jubilant Pharma Limited (JPL), a material wholly owned subsidiary of the company, through one of its wholly owned subsidiaries, has successfully completed the acquisition of the US radiopharmacy business of Triad Isotopes, Inc. The acquisition is a strategic fit to Jubilant's niche nuclear medicine business and will provide the company with direct access to hospital networks with ability to deliver more than 3 Million patient doses annually through approximately 1,700 customers. The company intends to maintain and expand Triad's distribution network. Triad operates the second largest radiopharmacy network in the US with more than 50 pharmacies. Triad recorded revenues in excess of US$ 225 Million in CY2016 with positive EBITDA and the acquisition is likely to be earnings accretive. This acquisition is funded through JPL's internal accruals with no increase in debt for Jubilant Life Sciences Limited.

On 29 November 2017, Jubilant Biosys Ltd., a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd., announced that it has successfully achieved an early stage milestone related to a collaborative program with Sanofi in Frankfurt, Germany focused on metabolic disorders. The milestone reflects the successful transition of a collaborative program to the next phase in the discovery and development process. This alliance is part of a portfolio of programs, which began in 2016, focused on the discovery and development of small molecule inhibitors for multiple targets designed to address the unmet medical needs in diabetes and obesity. Jubilant Biosys confirmed receiving payment for the first milestone achievement for this collaboration. Jubilant Biosys will continue to apply its effective integrated drug discovery platform to generate novel molecules that can demonstrate clinical proof-of-mechanism.

As on March 31, 2019, the Company had 50 subsidiaries.

As on 31st March 2020, the Company had 44 commercial products and filed 97 Drug Master Files (DMFs) in the US, 44 CEPs in Europe, 40 DMFs in Canada, 15 Japanese DMFs and 14 filings in Australia.

During the year 2020, Company increased the oral solid dosage capacity at their manufacturing facility in Roorkee, India by 1 billion doses to meet the growth requirements. It commercialised two new proprietary products during the year. It manufactured 3 new CDMO intermediates for US and Japan innovator companies which were 100% On-Time and In-Full (OTIF) due to improved system procedures. Further, it launched health supplement products in the US market.

During the year 2020, Company transferred, by way of slump-sale, its India Branded Pharmaceuticals Business on a going concern basis to Jubilant Generics Limited, a wholly-owned subsidiary of the Company.

As on March 31, 2020, the Company had 48 subsidiaries.

The Company was also engaged in the Life Science Ingredients business till 1 February 2021. The Composite Scheme of Arrangement for amalgamation of certain promoter controlled entities into the Company and demerger of the Life Science Ingredients business into Jubilant Ingrevia Limited, the Resulting entity, was approved by Hon'ble National Company Law Tribunal (NCLT), Allahabad Bench vide its Order dated 23 December 2020. The said NCLT Order was filed with the Registrar of Companies by the Company and the Resulting entity on 1 February 2021, thereby making the Composite Scheme effective. Effective 1st February, 2021 the Life Science Ingredients business demerged from Jubilant Pharmova Limited and name of the Company changed to Jubilant Pharmova Limited from Jubilant Life Sciences Limited effective from that date.

In August 2021, the Company completed the chemistry research capacity expansion in Greater Noida and commissioned the new capacity.

As on March 31, 2021, the Company had 39 subsidiaries.

During the Financial Year 2020-21, Jubilant entered into a non-exclusive voluntary licensing agreement with Gilead to register, manufacture and sell Gilead's investigational drug Remdesivir in 127 countries including India, as a potential therapy for COVID-19 treatment. After getting approval from the Drug Controller General of India to manufacture and market the antiviral drug Remdesivir, JGL launched the lyophilized injection under its own brand name 'JUBI-R' and was able to manufacture in-house Remdesivir API.

As on March 31, 2022, the Company had 35 subsidiaries. As on March 31, 2022, there were 13 products marketed in the US with focus in the therapeutic areas of CVS, CNS, Anti Allergic, Steroids, etc.

As of March 2022, Company filed 98 Drug Master Files (DMFs) in the US, 46 Certification of Suitability (CEPs) in Europe, 40 DMFs in Canada, 15 DMFs in Japan and 14 DMFs in Australia.

In May 2022, the Company announced another expansion at the Spokane facility, to increase the injectable filling production capacity at the plant by 100% from current levels at a cost of US$ 192 million.

During the year 2022, the Company voluntarily withdrew Losartan and Losartan HCTZ product from the US market following detection of a new category of azido impurities.

During the year 2022, the Company commissioned the state-of-the-art Chemistry Innovation Research Centre at Greater Noida, India to double the chemistry research capacity.

During the year 2022-23, the Scheme of Arrangement between Jubilant Generics Limited (JGL) and the Company for Demerger of Active Pharmaceuticals Ingredients (API) undertaking/business of JGL and vesting of the same with the Company on a going concern basis with an Appointed Date of April 1, 2022 became effective on July 1, 2022.

During the year 2022-23, the I131-MIBG program for high-risk neuroblastoma made significant progress with record-high enrolment of patients in the OPTIMUM Phase II clinical trial. In 2023, the Company received the US FDA approval to use RUBY Rubidium Elution System and RUBY-FILL (Rubidium Rb82 generator) in mobile settings. In May 2022, it expanded the facility at Spokane to increase the total injectable filling production capacity.

During the year 2023, the Chemistry Innovation Research Centre at Greater Noida, India, was further expanded by 7000 sqft to provide in vitro ADME services to complement the chemistry service.

Parent organization Jubilant Bhartia Group
NSE symbol JUBLPHARMA
Founded 1978
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Jubilant Pharmova Ltd?

Answer Field

The share price of Jubilant Pharmova Ltd for NSE is ₹ 885.1 and for BSE is ₹ 897.3.

What is the Market Cap of Jubilant Pharmova Ltd?

Answer Field

The market cap of Jubilant Pharmova Ltd for NSE is ₹ 1,40,15.62 Cr. and for BSE is ₹ 1,42,08.81 Cr. as of now.

What is the 52 Week High and Low of Jubilant Pharmova Ltd?

Answer Field

The 52 Week High and Low of Jubilant Pharmova Ltd for NSE is ₹ 1309.90 and ₹ 617.05 and for BSE is ₹ 1309.00 and ₹ 616.85.

How to Buy Jubilant Pharmova Ltd share?

Answer Field

You can trade in Jubilant Pharmova Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Jubilant Pharmova Ltd?

Answer Field

The 1 year returns on the stock has been 33.18%.

What is the Current Share Price of Jubilant Pharmova Ltd?

Answer Field

Jubilant Pharmova Ltd share price is for NSE ₹ 885.1 & for BSE ₹ 897.3 as on Apr 30 2025 03:29 PM.

What is the Market Cap of Jubilant Pharmova Ltd Share?

Answer Field

The market cap of Jubilant Pharmova Ltd for NSE ₹ 1,40,15.62 & for BSE ₹ 1,42,08.81 as on Apr 30 2025 03:29 PM.

What is the P/E Ratio of Jubilant Pharmova Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM the price-to-earnings (PE) ratio for Jubilant Pharmova Ltd share is 375.44.

What is the PB ratio of Jubilant Pharmova Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM, the price-to-book (PB) ratio for Jubilant Pharmova Ltd share is 144.29.

How to Buy Jubilant Pharmova Ltd Share?

Answer Field

You can trade in Jubilant Pharmova Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Jubilant Pharmova Ltd Share on Bajaj Broking App?

Answer Field

To buy Jubilant Pharmova Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Jubilant Pharmova Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|